• Practicing Personalized Evidence-Based Medicine in CLL through Risk Stratification and Patient Education - Register Today!
  • Managing Myeloma LIVE Clincal DIscussion Series - Register Today!
  • On-demand adaptation of Relapsed/Refractory MM live meeting series
  • The Role of CD30: New Frontiers in Targeting Therapy for Malignant Lymphomas

What's New

CE Education
Empowering Community Oncologists in the New Era of Cancer Management:
ADAPTATION OF THE IMMUNO-ONCOLOGY REGIONAL MEETING SERIES

Bradley C. Carthon, MD, PhD; Jason J. Luke, MD, FACP; Jeffrey S. Weber, MD, PhD
CE Education
Individualizing Therapeutic Options and Achieving Goals in Chronic Lymphocytic Leukemia (CLL)
Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD; Peter Hillmen, MD, FRCP, FRCPath, PhD; Thomas J. Kipps, MD
CE Education
Expert Strategies in Mantle Cell Lymphoma: Age-based Differential Approaches to Induction Therapy
Julie M. Vose, MD, MBA – Chair; John P. Leonard, MD; Brad S. Kahl, MD
CE Education
Evolving Treatment Paradigms in Chronic Lymphocytic Leukemia: Challenging Cases and Expert Strategies
Susan M. O’Brien, MD – Chair; John C. Byrd, MD; Nicole Lamanna, MD
CE Education
Aligning Current Practice in Febrile Neutropenia with Guideline-based Care
James O. Armitage, MD – Moderator; R. Donald Harvey, PharmD, FCCP, BCOP; Gary H. Lyman, MD, MPH, FASCO
FAQ Library
What are the recommended management strategies for patients with low-risk febrile neutropenia?
Christopher R. Flowers, MD

What is the incidence of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP

How do you define chemotherapy-related febrile neutropenia?
R. Donald Harvey, III, PharmD, FCCP, BCOP

What are the risk factors for the development of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP